Purpose: This study aimed to assess the effect of intravenous dexmedetomidine (DEX) on sevoflurane EC₅₀ for supraglottic airway device (SAD) insertion in spontaneously breathing morbidly obese patients.
Patients and methods: Thirty-eight morbidly obese patients with a body mass index 40–57 kg/m² who were scheduled for bariatric surgery under general anesthesia requiring tracheal intubation were randomly allocated to two groups receiving the different treatments: group S, saline was given intravenously, and group D, a bolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous DEX infusion at a rate of 0.5 μg/kg/h. Five percent sevoflurane was initially inhaled for anesthesia induction and then end-tidal expiratory sevoflurane concentration (ET_sev) was adjusted to a target value as to the modified Dixon’s up-and-down method. Patients’ response to SAD insertion was classified as “movement” or “no movement”. The average of the midpoints of all crossover points was defined as calculated sevoflurane EC₅₀ for successful SAD insertion. Furthermore, the probit regression analysis was used to determine sevoflurane end-tidal concentrations where 50% (EC₅₀) and 95% (EC₉₅) insertions of SAD were successful. After the observation was completed, flexible bronchoscope-guided intubation was performed through the SAD.
Results: The calculated sevoflurane EC₅₀ for successful SAD insertion was significantly lower in group D than in group S (1.75±0.32% vs  2.92±0.26%, p <0.001). By the probit regression analysis, EC₅₀ and EC₉₅ of sevoflurane for successful SAD insertion were 1.59% (95% CI, 1.22–1.90%) and 2.15% (95% CI, 1.86–3.84%) in group D, respectively, and 2.81% (95% CI, 2.35–3.29%) and 3.32% (3.02–6.74%) in group S.
Conclusion: When sevoflurane inhalational induction is performed in spontaneous breathing morbidly obese patients, intravenous DEX can reduce sevoflurane EC₅₀ for successful SAD insertion by about 40%.
Chinese Clinical Trial Registry: No. ChiCTR1800016868
Keywords: obesity, inhalational induction, sevoflurane, dexmedetomidine, supraglottic airway device